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Abstract 
The effect of exogenous growth hormone (GH) treatment on the growth of juvenile yellow 
perch (Perca flavescens) was investigated in four experiments. In the first two experiments 
juvenile yellow perch were reared at either 13°C or 21°C, and injected weekly with bovine 
GH (bGH) at 0.1, 1.0 or 10.0 μg/g body weight for 84 days. No significant growth 
enhancement in GH-treated fish was measured in fish in either of the experiments. In the third 
experiment, juvenile yellow perch were treated with estradiol-17β (E2, 15 μg/g of diet), bGH 
(1.0 μg/g body weight) injected weekly, or both hormones for 70 days at 21°C. E2 alone 
stimulated growth, but no further growth stimulation occurred in the E2 + bGH treated fish. In 
addition, no growth enhancement was found in fish treated with bGH alone. We measured no 
difference in serum insulin-like growth factor-I (IGF-I) levels between the treatment groups at 
12 and 24 h after the final injection of GH, however, a drop in IGF-I levels after 24 h was 
revealed. In a fourth study, the effect of recombinant yellow perch GH (rypGH, 0.2 or 1.0 
μg/g body weight) injected weekly was evaluated in yellow perch juveniles. The fish were 
reared for 42 days at 18°C. Neither dose of growth hormone improved growth compared to 
control-injected and non-injected fish. Taken together, the lack of effect of mammalian GH or 
rypGH in our experiments suggest (1) low-affinity between these hormones and the GH 
receptor in yellow perch, (2) that the endogenous GH levels were already at biologically 
maximal levels, or (3) that other endocrine factors are needed in order for GH to promote 
yellow perch growth. The reduction in IGF-I levels 24 h after handling suggests a negative 
effect of handling stress on the GH-IGF-I axis in yellow perch. 
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1. Introduction 
The yellow perch (Perca flavescens) is a popular food fish in the mid-western United States, 
and an important aquaculture industry has emerged to supply the high market demand for this 
species. A major constraint to the expansion of this industry, however, is the slow growth rate 
of yellow perch (Malison et al., 2003). To date, research directed at improving the growth of 
cultured yellow perch has focused on producing all-female stocks, as female yellow perch 
grow significantly faster than males (Schott et al., 1978; Malison et al., 1988). Sex steroids 
regulate this sexually dimorphic growth pattern. Estradiol-17β (E2) and androgens have 
positive and negative effects on growth, respectively (Malison et al., 1985; Malison et al., 
1987; Malison et al., 1988). E2 appears to promote growth in yellow perch by stimulating 
appetite (Malison et al., 1988), and enhancing the production of growth hormone (GH) 
(Roberts et al., 2004). Roberts et al. (2004) recently cloned and sequenced the yellow perch 
GH gene, and showed that the pituitary GH content increases markedly in the early spring, 
coincident with a dramatic increase in the growth rate of the fish. Other than these data, very 
little is known about the role of GH in mediating growth in yellow perch. 
 
Growth in fish is primarily regulated by the GH-insulin-like growth factor-I (IGF-I) axis 
(Björnsson, 1997; Duan, 1998; Moriyama et al., 2000). Hypothalamic hormones control the 
pituitary production of GH (Donaldson et al., 1979; Harvey, 1993; Peter and Marchant, 1995), 
which, in turn, stimulates hepatic production of IGF-I, the principal mediator of somatic 
growth (Duan, 1998; Moriyama et al., 2000). The GH-IGF-I axis is well conserved in 
vertebrate evolution, and the structure and the biological potency of piscine IGF-Is are similar 
to their mammalian homologs (Duan, 1998). The exogenous administration of various 
mammalian and piscine GHs, both native and recombinant, have been shown repeatedly to 
increase the growth rates of teleosts (see reviews Donaldson et al., 1979; McLean and 
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Donaldson, 1993). To better understand the function of the GH-IGF-I axis in yellow perch, 
the effects of exogenous bovine GH (bGH) and recombinant yellow perch GH (rypGH) 
treatment on growth and serum levels of IGF-I were investigated in juvenile yellow perch. 
 
2. Materials and methods 
2.1 Experiments 1 and 2 
Juvenile yellow perch obtained from Willow Creek Aquaculture, LLC, Berlin, WI, USA were 
acclimated to either 13°C (Experiment 1) or 21°C (Experiment 2) at the University of 
Wisconsin-Madison, Madison, WI, USA, over a 4-week period. For each temperature, 64 fish 
were randomly distributed into eight 110-L flow-through tanks. The eight fish in each tank 
were individually fin clipped. At the start of experiments 1 and 2, the mean fish weights were 
11.4 ± 0.5g and 13.8 ± 0.4g, respectively. The fish were divided into four treatments groups; 
two tanks per treatment, injected weekly with either purified bGH (National Hormone and 
Peptide Program, USA) at 0.1, 1.0, or 10.0 μg/g body weight or saline water as control, and 
raised for 84 days. The bGH was dissolved in 0.85% NaCl (pH = 9.5), and the injection 
volume was 100 μl/10 g body weight for all treatment groups. The bGH shared 35% sequence 
identity to the native yellow perch GH (Roberts et al., 2004). The light intensity was the same 
in all treatment groups and the photoperiod was constant L:D 16:8. The fish were hand-fed 
twice a day approximately 4% of body weight per day (Silver Cup trout food, Murray, Utah). 
Body weight and length of individual fish were recorded every third week. In experiment 2 
the sex of each fish was determined at the end of the study. 
 
2.2 Experiment 3 
Age 1+ yellow perch (Willow Creek Aquaculture, LLC, Berlin, WI, USA) were acclimated to 
21°C at the University of Wisconsin-Madison, Madison, WI, USA for 4 weeks. The fish (n = 
 5
124) were individually PIT-tagged, and randomly distributed into twelve 110-L flow through 
tanks at 10 or 11 fish in each tank. In addition, 5 or 6 untagged fish were distributed to 
achieve a rearing density of 16 fish per tank. At the start of the experiment the average fish 
weight was 33.9 ± 0.7g. There were four treatment groups replicated three times: injected 
weekly with saline, E2 (15 μg/g of diet) in combination with weekly injections of saline, 
purified bGH (National Hormone and Peptide Program, USA) (1.0 μg/g body weight) injected 
weekly, or both hormones. The experiment was conducted for 70 days. E2 was administrated 
via the diet according to the method of Malison et al. (1985). The bGH was dissolved in 
0.85% NaCl (pH = 9.5), and the injection volume was 100 μl/30 g body weight for all 
treatment groups. The light intensity was the same in all treatment groups and the photoperiod 
was constant L:D 16:8. The fish were hand-fed twice a day approximately 3% of body weight 
per day (Silver Cup trout food, Murray, Utah). Body weight and length of the tagged fish 
were recorded every second week. The sex of each fish was determined at the end of the 
study. 
 
After the final weight and length measurements, an additional injection of bGH (1.0 μg/g 
body weight) was administrated to the bGH treated fish, and blood samples were collected 
from all treatment groups 12 (n = 6) and 24 (n = 3) h post-injection. The blood samples were 
allowed to clot at 4°C overnight, centrifuged at 3,000 × g for 20 min, and the serum samples 
were collected and stored at -40°C until assayed for IGF-I. The levels of IGF-I were measured 
in triplicate by using a commercial fish IGF-I radioimmunoassay (RIA) kit according to the 
manufacturer’s instructions (GroPep, Australia). The RIA kit uses recombinant tuna IGF-I as 
radiolabeled tracer (125I) and standard. The assay kit was validated for measuring yellow 
perch IGF-I by verifying that serial dilutions of yellow perch serum inhibited the binding of 
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radiolabeled IGF-I in parallel with the IGF-I standards. Serum samples were extracted with 
acid ethanol to remove IGF-I binding proteins. 
 
2.3 Experiment 4 
Age 1+ yellow perch (n = 96) hatched and reared at the University of Wisconsin-Madison, 
Lake Mills, WI, USA, were randomly distributed into twelve 110-L flow-through tanks for a 
five-week acclimatization period. The eight fish in each tank were individually fin clipped. 
The fish (initial mean weight = 11.4 ± 0.5g) were reared for 42 days at 18°C. There were four 
treatment groups replicated three times: rypGH injected weekly at 0.2 μg/g body weight, 
rypGH injected weekly at 1.0 μg/g body weight, injected control or un-injected control. The 
rypGH was dissolved in D1-Dithiothreitol (DTT); which was also used as the control 
injection. The injection volume was 100 μl/10 g body weight. The rypGH shared 100% 
sequence identity to the native yellow perch GH (Roberts et al., 2004). The light intensity was 
the same in all treatment groups and the photoperiod was constant L:D 16:8. The fish were 
hand-fed twice a day approximately 4% of body weight per day (Silver Cup trout food, 
Murray, Utah). Body weight and length of individual fish were recorded every third week. 
The sex of each fish was determined at the end of the study. 
 
2.4 Statistics 
Weight and length gain were analyzed by a one-way (treatment, Experiment 1) or two-way 
(treatment and sex, Experiments 2, 3 and 4) ANOVA. Differences in growth rates between the 
treatment groups were further examined by LSD (least significant difference). Serum IGF-I 
levels were analyzed by a two-way ANOVA (treatment and sex), and IGF-I levels were 
correlated (linear regression) with weight gain. The level of significance used for all tests was 
P < 0.05. 
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3. Results 
3.1 Experiment 1 
No differences in weight or length gain were found between the control fish and the bGH-
treated fish (Fig. 1a and b), regardless of treatment dose. 
 
3.2 Experiment 2 
No differences in weight or length gain were found between any of the GH treatment groups 
(Fig. 2a and b). For all treatments females grew faster than males, and there was no treatment 
× sex interaction (data not shown). 
 
3.3 Experiment 3 
E2 had a positive effect on growth in both females and males, while no effect of bGH was 
found (Fig. 3a and b). Fish treated with a combination of E2 and bGH showed no further 
growth enhancement compared to the fish treated with E2 alone (Fig. 3a and b). In all 
treatments females grew faster than males (data not shown), and no treatment × sex 
interaction was found. There was no effect of hormone treatment on serum IGF-I levels 
(Table 1) at either 12 or 24 h post-injection, although IGF-I levels were lower at 24 h post-
injection than at 12 h post-injection (Table 1). Furthermore, there were no differences in IGF-
I levels between females and males in any of the treatment groups. No correlation between 
IGF-I levels and weight gain was measured (data not shown). 
 
3.4 Experiment 4 
Yellow perch treated with rypGH at 1.0 μg/g body weight gained less weight and length than 
fish in the other treatment groups, while no growth differences were found between un-
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injected control fish, injected control fish and fish treated with rypGH at 0.1 μg/g body weight 
(Fig. 4a and b). There was no main effect of sex, nor was there a treatment × sex interaction. 
 
4. Discussion 
The failure of bGH or homologous rypGH treatment to promote growth in yellow perch is in 
contrast to other fish species in which exogenous GH treatment markedly stimulates growth 
under both optimal (Weatherley and Gill, 1987; Skyrud et al., 1989; Silverstein et al., 2000; 
Hunt et al., 2000) and sub-optimal (Adelman, 1977; Kelly et al., 1996; Leedom et al., 2002) 
rearing conditions. Further, the GH treatments induced no increase in IGF-I levels in our 
studies, as has been shown in several other fish species (Cao et al., 1989; Funkenstein et al., 
1989; Moriyama, 1995; Moriyama et al., 1995; Shamblott et al., 1995). A positive correlation 
between IGF-I levels and growth has also been demonstrated in teleosts (Duan et al., 1995; 
Silverstein et al., 2000; Pierce et al., 2001; Kajimura et al., 2001; Uchida et al., 2003). 
However, the lack of correlation between IGF-I levels and weight gain found in yellow perch 
has also been demonstrated in the closely related species gilthead seabream (Sparus aurata) 
(Metón et al., 2000). 
 
Because of the wide range of doses and conditions tested, we do not believe that the failure of 
GH to promote growth in our experiments was due to methodological problems, such as 
improper dose or rearing conditions. Rather, one explanation for our results is that neither 
bGH nor rypGH bind and/or activate the GH receptor in yellow perch. In tilapia 
(Oreochromis mossambicus) recombinant bGH showed low-binding affinity to the GH 
receptor relatively to the native tilapia GH (Ng et al., 1992; Leedom et al., 2002). With regard 
to our results with rypGH, we suggest that the protein may have been improperly folded to 
interact with the GH receptor. The poor growth achieved when treated with high dosages of 
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rypGH could indicate that the protein was blocking the GH receptors, and competing with 
native yellow perch GH. 
 
A second explanation of our results is that the 16:8 L:D photoperiod used in all four of our 
experiments may have promoted maximal endogenous GH synthesis and release in yellow 
perch, resulting in insensitivity to additional exogenous GH treatment. Extrinsic factors such 
as photoperiod and temperature were shown by Roberts et al. (2004) to influence the GH 
content in the pituitary of yellow perch, reaching a peak level in May. In Eurasian perch 
(Perca fluviatilis) the GH pituitary content was also shown to reach maximum levels in 
May/June at the time of longest photoperiod (Swift and Pickford, 1965). Additionally, long 
photoperiod (18:6 or 24:0 L:D) has been documented to strongly enhance the growth 
performance in juvenile Eurasian perch (Jourdan et al., 2000). 
 
A third possible explanation for our results is that other endocrine factors are needed in order 
for GH to promote yellow perch growth. Because of its growth-promoting ability in yellow 
perch, we postulated that exogenous E2 might work in concert with GH to stimulate growth. 
We found, however, that bGH induced no further growth enhancement in E2-treated yellow 
perch. Additionally, the serum IGF-I levels were no higher in fast growing E2-treated fish 
than in bGH treated fish or control fish, nor in fast growing females than in males. This 
finding supports the hypothesis that the growth-promoting effects of E2 in yellow perch are 
probably not mediated via IGF-I. Roberts et al. (2004), however, reported that E2 treatment 
increased pituitary levels of GH. In other fish species sex steroids have been documented to 
mediate the GH-IGF-I axis (Holloway and Leatherland, 1997a; Holloway and Leatherland, 
1997b; Riley et al., 2002), and estrogens are documented to affect the levels of IGF binding 
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proteins (IGFBPs) (Fukazawa et al., 1995). Thus, the positive effect of estrogens on growth in 
yellow perch could be mediated by the GH-IGF-I axis through actions of IGFBPs. 
 
A fourth reason for the lack of an effect of GH on growth in our studies could be related to 
negative effect of handling stress. In Experiment 4, we found no negative effects of injections 
per se on growth. All potential negative effects of handling cannot be ruled out, however, 
since all groups of fish including the un-injected control fish were handled once a week at the 
time of the injection. Yellow perch are known to have a powerful cortisol response to 
handling stress (Head and Malison, 2000), and cortisol has been documented to reduce the 
levels of IGF-I in tilapia (Kajimura et al., 2003). Serum IGF-I levels decrease one to two days 
after handling in several fish species, including Atlantic salmon (Salmo salar), silver perch 
(Bidyanus bidyanus), and black bream (Acanthopagrus butcheri) (Dyer et al., 2004). Our 
findings that IGF-I levels declined from 12 to 24 h after the final injection suggests that IGF-I 
levels may be impacted by handling stress in yellow perch. 
 
Acknowledgements 
This work was supported by the University of Wisconsin-Madison College of Agricultural 
and Life Sciences and School of Natural Resources; the Wisconsin Department of Natural 
Resources; the University of Wisconsin Sea Grant College Program, National Oceanic and 
Atmospheric Administration, US Department of Commerce; the State of Wisconsin (Federal 
Grant NA46RG0481, Project No. R/AQ-38); and the USDA NOAA Project R/A-05-99, grant 
#NA86RG0048 to FG and SR. This study was also funded by the Norwegian Research 
Council (NFR). We thank Roar Elvegård for good assistance at the fish lab and Jennifer 
Bunner for helping with the IGF-I measurements. We also acknowledge NIDDK´s National 
Hormone & Peptide Program and Dr. A.F. Parlow for the shipment of purified bovine GH. 
 11
 
References 
Adelman, I. R., 1977. Effects of bovine growth hormone on growth of carp (Cyprinus carpio) 
and the influences of temperature and photoperiod. J . Fish Res. Board Can. 34, 509-
515. 
Björnsson, B. Th., 1997. The biology of salmon growth hormone: From daylight to 
dominance. Fish Physiol. Biochem. 17, 9-24. 
Cao, Q.-P., Duguay, S. J., Plisetskaya, E., Steiner, D. F., Chan, S. J., 1989. Nucleotide 
sequence and growth hormone-regulated expression of salmon insulin-like growth 
factor I mRNA. Mol. Endocrinol. 3, 2005-2010. 
Donaldson, E. M., Fagerlund, U. H. M., Higgs, D. A., McBride, J. R., 1979. Hormonal 
enhancement of growth. In: Hoar, W. S., Randall, D. J., and Brett, J. R. (Eds), Fish 
Physiology. Bioenergetics and growth. Academic Press, New York, pp. 455-597. 
Duan, C., 1998. Nutritional and developmental regulation of insulin-like growth factors in 
fish. J. Nutr. 128, 306S-314S. 
Duan, C., Plisetskaya, E. M., Dickhoff, W. W., 1995. Expression of insulin-like growth factor 
I in normally and abnormally developing coho salmon (Oncorhynchus kisutch). 
Endocrinology 136, 446-452. 
Dyer, A. R., Upton, Z., Stone, D., Thomas, P. M., Soole, K. L., Higgs, N., Quinn, K., 
Carragher, J. F., 2004. Development and validation of a radioimmunoassay for fish 
insulin-like growth factor I (IGF-I) and the effect of aquaculture related stressors on 
circulating IGF-I levels. Gen. Comp. Endocrinol. 135, 268-275. 
 12
Fukazawa, Y., Siharath, K., Iguchi, T., Bern, H. A., 1995. In vitro secretion of insulin-like 
growth factor-binding proteins from liver of striped bass, Morone saxatilis. Gen. 
Comp. Endocrinol. 99, 239-247. 
Funkenstein, B., Silbergeld, A., Cavari, B., Laron, Z., 1989. Growth hormone increases 
plasma levels of insulin-like growth factor (IGF-I) in a teleost, the gilthead seabream 
(Sparus aurata). J. Endocrinol. 120, R19-R21. 
Harvey, S., 1993. Growth hormone secretion in poikilotherms and homeotherms. In: 
Schreibman, M. P., Scanes, C. G., and Pang, P. K. T. (Eds), The endocrinology of 
growth, development, and metabolism in vertebrates. Academic Press, San Diego, pp. 
151-182. 
Head, A. B., Malison, J. A., 2000. Effects of lighting spectrum and disturbance level on the 
growth and stress responses of yellow perch Perca flavescens. J. World Aquacult. Soc. 
31, 73-80. 
Holloway, A. C., Leatherland, J. F., 1997a. Estradiol inhibits plasma somatostatin 14 (SRIF-
14) levels and inhibits the response of somatotrophic cells to SRIF-14 challenge in 
vitro in rainbow trout, Oncorhynchus mykiss. Gen. Comp. Endocrinol. 106, 407-414. 
Holloway, A. C., Leatherland, J. F., 1997b. The effects of N-methyl-D,L-aspartate and 
gonadotropin-releasing hormone on in vitro growth hormone release in steroid-primed 
immature rainbow trout, Oncorhynchus mykiss. Gen. Comp. Endocrinol. 107, 32-43. 
Hunt, A. S., Soares, J. H. Jr., Byatt, J. C., Dahl, G. E., 2000. The effects of exogenous bovine 
growth hormone and placental lactogen on juvenile striped bass Morone saxatilis feed 
and growth efficiency. J. World Aquacult. Soc. 31, 14-21. 
 13
Jourdan, S., Fontaine, P., Boujard, T., Vandeloise, E., Gardeur, J. N., Anthouard, M., 
Kestemont, P., 2000. Influence of daylength on growth, heterogeneity, gonad 
development, sexual steroid and thyroid levels, and N and P budgets in Perca 
fluviatilis. Aquaculture 186, 253-265. 
Kajimura, S., Hirano, T., Visitacion, N., Moriyama, S., Aida, K., Grau, E. G., 2003. Dual 
mode of cortisol action on GH/IGF-I/IGF binding proteins in the tilapia, Oreochromis 
mossambicus. J. Endocrinol. 178, 91-99. 
Kajimura, S., Uchida, K., Yada, T., Riley, L. G., Byatt, J. C., Collier, R. J., Aida, K., Hirano, 
T., Grau, E. G., 2001. Stimulation of insulin-like growth factor-I production by 
recombinant bovine growth hormone in Mozambique tilapia, Oreochromis 
mossambicus. Fish Physiol. Biochem. 25, 221-230. 
Kelly, A. M., Kohler, C. C., Grau, E. G., 1996. A mammalian growth hormone-releasing 
hormone increases serum growth hormone levels and somatic growth at suboptimal 
temperatures in tilapia. J. World Aquacult. Soc. 27, 384-401. 
Leedom, T. A., Uchida, K., Yada, T., Richman, N. H. I., Byatt, J. C., Collier, R. J., Hirano, T., 
Grau, E. G., 2002. Recombinant bovine growth hormone treatment of tilapia: Growth 
response, metabolic clearance, receptor binding and immunoglobulin production. 
Aquaculture 207, 359-380. 
Malison, J. A., Best, C. D., Kayes, T. B., Amundson, C. H., Wentworth, B. C., 1985. 
Hormonal growth promotion and evidence for a size-related difference in response to 
estradiol-17β in yellow perch (Perca flavescens). Can. J. Fish. Aquat. Sci. 42, 1627-
1633. 
 14
Malison, J. A., Kayes, T. B., Wentworth, B. C., Amundson, C. H., 1987. Control of sexually 
related dimorphic growth by gonadal steroids in yellow perch (Perca flavescens). In: 
Idler, D. R., Crim, L. W., and Walsh, J. M. (Eds), Proceedings of the Third 
International Symposium on Reproductive Physiology of Fish. Memorial University 
of Newfoundland, St. John's, Newfoundland, p. 206. 
Malison, J. A., Kayes, T. B., Wentworth, B. C., Amundson, C. H., 1988. Growth and feeding 
responses of male versus female yellow perch (Perca flavescens) treated with 
estradiol-17β . Can. J. Fish. Aquat. Sci. 45, 1942-1948. 
Malison, J. A., Kestemont, P., Summerfelt, R. C., 2003. Percid aquaculture: Current status 
and future research needs. In: Barry, T. P. and Malison, J. A. (Eds), Proceedings of 
Percis III: The third international Percid Fish Symposium. University of Wisconsin 
Sea Grant Institute, Madison, WI., p. 1. 
McLean, E., Donaldson, E. M., 1993. The role of growth hormone in the growth of 
poikilotherms. In: Schreibman, M. P., Scanes, C. G., and Pang, P. K. T. (Eds), The 
endocrinology of growth, development, and metabolism in vertebrates. Academic 
Press, San Diego, pp. 43-71. 
Metón, I., Caseras, A., Cantó, E., Fernández, F., Baanante, I. V., 2000. Liver insulin-like 
growth factor-I mRNA is not affected by diet composition or ration size but shows 
diurnal variations in regularly-fed gilthead sea bream. J. Nutr. 130, 757-760. 
Moriyama, S., 1995. Increased plasma insulin-like growth factor-I (IGF-I) following oral and 
intraperitoneal administration of growth hormone to rainbow trout, Oncorhynchus 
mykiss. Growth Regul. 5, 164-167. 
 15
Moriyama, S., Ayson, F. G., Kawauchi, H., 2000. Growth regulation by insulin-like growth 
factor-I in fish. Biosci. Biotechnol. Biochem. 64, 1553-1562. 
Moriyama, S., Dickhoff, W. W., Plisetskaya, E. M., 1995. Isolation and characterization of 
insulin-like growth factor-I from rainbow trout, Oncorhynchus mykiss. Gen. Comp. 
Endocrinol. 99, 221-229. 
Ng, T. B., Leung, T. C., Cheng, C. H. K., Woo, N. Y. S., 1992. Growth hormone binding sites 
in tilapia (Oreochromis mossambicus) liver. Gen. Comp. Endocrinol. 86, 111-118. 
Peter, R. E., Marchant, T. A., 1995. The endocrinology of growth in carp and related species. 
Aquaculture 129, 299-321. 
Pierce, A. L., Beckman, B. R., Shearer, K. D., Larsen, D. A., Dickhoff, W. W., 2001. Effects 
of ration on somatotropic hormones and growth in coho salmon. Comp. Biochem. 
Physiol. Part B 128, 255-264. 
Riley, L. G., Hirano, T., Grau, E. G., 2002. Disparate effects of gonadal steroid hormones on 
plasma and liver mRNA levels of insulin-like growth factor-I and vitellogenin in the 
tilapia, Oreochromis mossambicus. Fish Physiol. Biochem. 26, 223-230. 
Roberts, S., Barry, T., Malison, J., Goetz, F., 2004. Production of a recombinantly derived 
growth hormone antibody and the characterization of growth hormone levels in yellow 
perch. Aquaculture 232, 591-602. 
Schott, E. F., Kayes, T. B., Calbert, H. E., 1978. Comparative growth of male versus female 
yellow perch fingerlings under controlled environmental conditions. Am. Fish. Soc. 
Spec. Publ. 11, 181-186. 
 16
Shamblott, M. J., Cheng, C. M., Bolt, D., Chen, T. T., 1995. Appearance of insulin-like 
growth factor mRNA in the liver and pyloric ceca of a teleost in response to 
exogenous growth hormone. Proc. Natl. Acad. Sci. USA 92, 6943-6946. 
Silverstein, J. T., Wolters, W. R., Shimizu, M., Dickhoff, W. W., 2000. Bovine growth 
hormone treatment of channel catfish: Strain and temperature effects on growth, 
plasma IGF-I levels, feed intake and efficiency and body composition. Aquaculture 
190, 77-88. 
Skyrud, T., Andersen, Ø., Alestrøm, P., Gautvik, K. M., 1989. Effects of recombinant human 
growth hormone and insulin-like growth factor 1 on body growth and blood 
metabolites in brook trout (Salvelinus fontinalis). Gen. Comp. Endocrinol. 75, 247-
255. 
Swift, D. R., Pickford, G. E., 1965. Seasonal variations in the hormone content of the pituitary 
gland of the perch, Perca fluviatilis L. Gen. Comp. Endocrinol. 5, 354-365. 
Uchida, K., Kajimura, S., Riley, L. G., Hirano, T., Aida, K., Grau, E. G., 2003. Effects of 
fasting on growth hormone/insulin-like growth factor I axis in the tilapia, 
Oreochromis mossambicus. Comp. Biochem. Physiol. Part A 134, 429-439. 
Weatherley, A. H., Gill, H. S., 1987. Growth increases produced by bovine growth hormone 
in grass pickerel, Esox americanus vermiculatus (Le Sueur), and the underlying 
dynamics of muscle fiber growth. Aquaculture 65, 55-66. 
 
 
 
 17
Figure legends 
Fig. 1.  Mean (a) weights (g) and (b) lengths (mm) of yellow perch reared at 13°C and 
injected weekly with bGH (Experiment 1). Data represent u ± SEM, n = 2. There were no 
differences between treatments. 
 
Fig. 2.  Mean (a) weights (g) and (b) lengths (mm) of yellow perch reared at 21°C and 
injected weekly with bGH (Experiment 2). Data represent u ± SEM, n = 2. There were no 
differences between treatments. 
 
Fig. 3.  Mean (a) weights (g) and (b) lengths (mm) of yellow perch treated with E2 at 15 μg/g 
diet and/or injected weekly with bGH at 1.0 μg/g body weight (Experiment 3). Data represent 
u ± SEM, n = 3. Fish treated with E2 grew faster than the other groups, and there were no 
other differences between treatments. 
 
Fig. 4.  Mean (a) weights (g) and (b) lengths (mm) of yellow perch injected weekly with 
rypGH (Experiment 4). Data represent u ± SEM, n = 3. Fish treated with rypGH at 1.0 μg/g 
body weight grew slower in weight and length than the other groups. 
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 22
Treatment IGF-I (ng/ml) 
12 h post-inj. 
IGF-I (ng/ml) 
24 h post-inj. 
Control Male 4.78 ± 0.46 1.13 ± 0.12 
Control Female 4.55 ± 0.38 1.50 ± 0.31 
E2 Male 5.47 ± 0.98 1.67 ± 0.37 
E2 Female 6.18 ±1.76 1.87 ± 0.32 
bGH Male 4.23 ± 0.55 2.10 ± 0.50 
bGH Female 5.30 ± 1.19 1.75 ± 0.15 
E2 + bGH Male 4.10 ± 0.49 1.90 ± 0.64 
E2 + bGH Female 6.30 ± 1.31 1.17 ± 0.09 
 
Table 1:  IGF-I serum levels (ng/ml) 12 and 24 h post bGH injection in yellow perch males 
and females. Data represent u ± SEM, 12 h post injection n = 6, and 24 h post injection n = 3. 
There were no differences between treatments. 
